Who are ACULAR's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cytotec, Topical Diclofenac gel 1%, Diclofenac 1%, Voltaren® Gel, morphine ,ketorolac, ABS.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/acular.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

ACULAR — Competitive Intelligence Brief

ACULAR (ACULAR) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NSAID (nonsteroidal anti-inflammatory drug). Area: Ophthalmology.

marketed NSAID (nonsteroidal anti-inflammatory drug) COX-1 and COX-2 Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

ACULAR (ACULAR) — University of South Alabama. Acular (ketorolac tromethamine) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and thereby decrease inflammation and pain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ACULAR TARGET	ACULAR	University of South Alabama	marketed	NSAID (nonsteroidal anti-inflammatory drug)	COX-1 and COX-2
Cytotec	Misoprostol	Pfizer	marketed	NSAID combined with prostaglandin analog	Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors	1988-01-01
Topical Diclofenac gel 1%	Topical Diclofenac gel 1%	University of California, Davis	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2
Diclofenac 1%	Diclofenac 1%	Daré Bioscience, Inc.	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2
Voltaren® Gel	Voltaren® Gel	Glenmark Pharmaceuticals Ltd. India	marketed	Topical NSAID	COX-1 and COX-2 enzymes
morphine ,ketorolac	morphine ,ketorolac	Jose Antonio Bernia Gil	marketed	Opioid analgesic + NSAID combination	Opioid receptors (μ, δ, κ); COX-1 and COX-2 enzymes
ABS	ABS	Teva Branded Pharmaceutical Products R&D, Inc.	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NSAID (nonsteroidal anti-inflammatory drug) class)

Depomed · 1 drug in this class
Dong-A ST Co., Ltd. · 1 drug in this class
Handok Inc. · 1 drug in this class
Imprimis Pharmaceuticals, Inc. · 1 drug in this class
Kunming Baker Norton Pharmaceutical Sales Co., Ltd. · 1 drug in this class
LEO Pharma · 1 drug in this class
Novartis · 1 drug in this class
Pfizer · 1 drug in this class
University of South Alabama · 1 drug in this class
ZARS Pharma Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ACULAR — Competitive Intelligence Brief. https://druglandscape.com/ci/acular. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab